Genentech Alerts Of Tracheoesophageal Fistula Risk In Avastin Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is updating FDA about emerging risk of tracheoesophageal fistula in small cell lung cancer patients treated with Avastin.
You may also be interested in...
Genentech Issues Avastin “Dear Health Care Provider” Letter On Esophageal Fistula Risk
Firm plans to update biologic’s labeling with more detailed fistula information.
Genentech Issues Avastin “Dear Health Care Provider” Letter On Esophageal Fistula Risk
Firm plans to update biologic’s labeling with more detailed fistula information.
Genentech/Biogen Idec Second Generation Anti-CD20 Marriage May Be On The Rocks
Dispute over rights to second generation anti-CD20 molecules could have a negative impact on development timelines, Genentech says.